Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
Clinical trial NCT04429321 · TERMINATED
Trial details
- NCT number
- NCT04429321
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-26
- Primary completion
- 2024-01-31
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.